cepharanthine has been researched along with Atherosclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adnan Iqbal, -; Anosh Tahir, -; Azfar Athar Ishaqui, -; Bilal Jawed, -; Muhammad Imran, -; Muhammad Osama, -; Rahila Najam, -; Saira Saeed Khan, -; Sumera Imran, -; Zeeshan Ahmed, - | 1 |
| Karki, R; Kim, DW; Paudel, KR | 1 |
2 other study(ies) available for cepharanthine and Atherosclerosis
| Article | Year |
|---|---|
The role of cepharanthine as an anti-atherosclerotic agent in rats.
Topics: Animals; Atherosclerosis; Benzylisoquinolines; Plaque, Atherosclerotic; Rats; Rats, Wistar | 2023 |
Cepharanthine inhibits in vitro VSMC proliferation and migration and vascular inflammatory responses mediated by RAW264.7.
Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Becaplermin; Benzylisoquinolines; Biphenyl Compounds; Cell Movement; Cell Proliferation; Cells, Cultured; Cyclooxygenase 2; Dinoprostone; Humans; Iron; Lipid Peroxidation; Mice; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nitric Oxide; Nitric Oxide Synthase Type II; Picrates; Proto-Oncogene Proteins c-sis; RAW 264.7 Cells | 2016 |